De­nali re­ports a PhII ALS fail as RIPK1 deal with Sanofi hits an­oth­er bump

Sanofi and De­nali Ther­a­peu­tics’ part­ner­ship ran in­to yet an­oth­er stum­bling block af­ter their ALS pro­gram failed a Phase II study.

DNL788 did not achieve the pri­ma­ry end­point in the tri­al as it failed to show a dif­fer­ence in the re­vised ALS Func­tion­al Rat­ing Scale (ALS­FRS-R), ac­cord­ing to an SEC fil­ing on Fri­day. Ex­act da­ta fig­ures were not dis­closed, but De­nali not­ed that Sanofi in­tends to share the full re­sults at a fu­ture med­ical con­fer­ence.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER